Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma

Oncoimmunology 2025 December [Link] Sophie Rovers, Jonas Van Audenaerde, Ruben Verloy, Jorrit De Waele, Louize Brants, Christophe Hermans, Ho Wa Lau, Céline Merlin, Maria Möller Ribas, Peter Ponsaerts, Steven Van Laere, Filip Lardon, An Wouters, Scott A Fisher, Jan van Meerbeeck, Elly Marcq, Evelien Smits Abstract Pleural mesothelioma (PM) is an aggressive cancer caused by…

Read More

Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses

Pathology, Research, and Practice 2025 July [Link] Zhenghua Zhang, Wenjun Gao, Feng Yuan, Yubin Hu, Xiaoyu Tuo, Liangping Luo, Xiaonan Tang, Shasha Shen, Yang Tian, Dan Han Abstract Objective: Chemotherapy may modulate PD-L1 expression in malignant pleural mesothelioma (MPM), influencing immune checkpoint inhibitor (ICI) efficacy. We compared cisplatin (CDDP) and pemetrexed (PEM) on PD-L1 dynamics…

Read More

Dual Immunotherapy for Pericardial Mesothelioma That Developed After a Decade-Long Idiopathic Pericarditis: A Case Report

Respirology Case Reports 2024 May 26 [Link] Beatriz Grau Mirete, Paula Rodriguez Paya, Mariano Martinez Marin, Asia Ferrández Arias, Miguel Borregón Rivilla, Antonio David Lazaro Sanchez, Pedro Morillas Blasco, Alvaro Rodriguez-Lescure, Javier David Benítez Fuentes Abstract Malignant pericardial mesothelioma (MPeM) is exceptionally rare, and its association with long-standing idiopathic pericarditis remains unreported. We present a…

Read More

A bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023

Journal of Thoracic Cancer 2025 April 30 [Link] Sheng Chen, Ce Zhao, Ruiqi Liu, Wenjie Jiao Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor originating from the mesothelial lining of the pleural cavity. It is characterized by extensive nodular pleural thickening and has a propensity to invade the pleural adipose tissue and adjacent…

Read More

Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma

Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…

Read More

BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives

Cancers 2025 May 6 [Link] Susana Cedres, Augusto Valdivia, Ilaria Priano, Pedro Rocha, Patricia Iranzo, Nuria Pardo, Alex Martinez-Marti, Enriqueta Felip Abstract Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy…

Read More

Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma

International Journal of Molecular Sciences 2025 May 1 [Link] Taketo Kato, Ichidai Tanaka, Heng Huang, Shoji Okado, Yoshito Imamura, Yuji Nomata, Hirofumi Takenaka, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa Abstract Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in…

Read More

PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma

Cancer Research Communications 2025 May 1 [Link] Gwendolyn M Cramer, Richard W Davis 4th, Emmanouil Papasavvas, Astero Klampatsa, Joann M Miller, Shirron Carter, Ruth Ikpe, Min Yuan, Sandy Widura, R Sonali Majumdar, Sally McNulty, Mary Putt, Andrew V Kossenkov, Luis J Montaner, Sunil Singhal, Edmund K Moon, Steven M Albelda, Keith A Cengel, Theresa M…

Read More

Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

Medicina 2025 March 31 [Link] Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, Akin Ozturk, Murat Bardakci, Serdar Karakaya, Muhammet Ali Kaplan Abstract Background and Objectives: This study aimed to evaluate the effectiveness of immunotherapy compared to chemotherapy across…

Read More

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Current Treatment Options in Oncology 2025 May [Link] Giovanni Luca Ceresoli, Letizia Gianoncelli Abstract Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy (pemetrexed plus platinum) was standard of…

Read More